Private Capital Advisors Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 10.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,833 shares of the company’s stock after selling 1,175 shares during the period. Private Capital Advisors Inc.’s holdings in Johnson & Johnson were worth $1,278,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. OLD Point Trust & Financial Services N A grew its position in Johnson & Johnson by 2.2% in the 2nd quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after purchasing an additional 1,321 shares during the last quarter. Lynch & Associates IN boosted its holdings in shares of Johnson & Johnson by 0.9% in the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after acquiring an additional 841 shares in the last quarter. Welch & Forbes LLC boosted its holdings in shares of Johnson & Johnson by 0.9% in the second quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock valued at $95,028,000 after acquiring an additional 6,730 shares in the last quarter. Oakbrook Investments LLC boosted its holdings in shares of Johnson & Johnson by 7.4% in the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after acquiring an additional 9,375 shares in the last quarter. Finally, Janney Montgomery Scott LLC boosted its holdings in shares of Johnson & Johnson by 0.5% in the second quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock valued at $102,110,000 after acquiring an additional 3,533 shares in the last quarter. Hedge funds and other institutional investors own 65.70% of the company’s stock.

Several research firms have recently issued reports on JNJ. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price objective for the company in a report on Wednesday. BMO Capital Markets increased their price objective on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Citigroup increased their price objective on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a report on Monday, October 23rd. Finally, Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company an “outperform” rating in a report on Thursday, October 19th. Four analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $145.51.

Shares of Johnson & Johnson (NYSE JNJ) opened at $141.16 on Thursday. Johnson & Johnson has a one year low of $110.76 and a one year high of $144.35. The company has a market cap of $381,136.59, a P/E ratio of 19.87, a P/E/G ratio of 2.88 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same period in the prior year, the business earned $1.68 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. equities analysts predict that Johnson & Johnson will post 7.28 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.38%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

ILLEGAL ACTIVITY WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/private-capital-advisors-inc-reduces-position-in-johnson-johnson-jnj/1775671.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.